Annual revenue rose from KRW 55.5 billion in 2022 to KRW 69.4 billion in 2023 (up 25.1% year on year), KRW 96 billion in 2024 (up 38.4%) and KRW 149.2 billion in 2025 (up 55.4%). Revenue has grown for three consecutive years from 2023 through 2025, and 2025 was the largest year of the 2022 to 2025 period.
Operating results moved from an operating loss of KRW 3.77 billion in 2022 to an operating profit of KRW 7.7 billion in 2023, a swing to profit, then KRW 34.3 billion in 2024 (up 345.8%) and KRW 60.7 billion in 2025 (up 76.8%), which means operating profit has risen for two consecutive years from 2024 to 2025.
The operating margin went from -6.8% in 2022 to 11.1% in 2023, 35.7% in 2024 and 40.7% in 2025. In an early 2026 report, the CEO attributed the 2025 improvement to higher cholera vaccine shipments and a more stable production plant.
Profit attributable to controlling shareholders moved from a loss of KRW 1.1 billion in 2022 and a loss of KRW 13.9 billion in 2023, which widened the loss, to a profit of KRW 19 billion in 2024 (a swing to profit) and KRW 41.3 billion in 2025 (up 117.3%).
Net income including non-controlling interests was a loss of KRW 3.44 billion in 2022, a loss of KRW 15.4 billion in 2023, a profit of KRW 19 billion in 2024 and KRW 41.3 billion in 2025.
On a quarterly basis, revenue was KRW 41.1 billion with operating profit of KRW 18.9 billion in the third quarter of 2025, then KRW 32.3 billion and KRW 13.6 billion in the fourth quarter (revenue down 21.4% from the prior quarter).
The first quarter of 2026 was the trough, at KRW 15.6 billion in revenue and KRW 2.19 billion in operating profit. Third-quarter 2026 revenue of KRW 49.6 billion rose 20.6% year on year, and operating profit of KRW 21.9 billion rose 15.6%.
Before the release, KB Securities had estimated third-quarter revenue of KRW 48.5 billion and operating profit of KRW 20.2 billion, and SangSangin Securities had estimated KRW 47.9 billion and KRW 21.1 billion, and the disclosed figures came in above both.
Brokers attributed the first-half decline to a base effect from a temporary surge in cholera vaccine exports in the first half of 2025. Profit attributable to controlling shareholders over the latest four quarters, from the fourth quarter of 2025 to the third quarter of 2026, totals KRW 43.3 billion.
Total equity at the end of 2025 was KRW 175.4 billion, all attributable to controlling shareholders, and total liabilities were KRW 64.9 billion. The debt ratio fell from 53.1% in 2024 to 37.0% in 2025, and operating cash flow rose from KRW 6.44 billion in 2022 to KRW 49.1 billion in 2025.